GlaxoSmithKline: Irritable Bowel Syndrome trials

The registry lists 16 Irritable Bowel Syndrome studies with GlaxoSmithKline as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 1 5Phase 2 8Phase 3 2Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)RecruitingNCT07519395Phase 2
• A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy VolunteersCompletedNCT03154086Phase 1Results posted
• Sb-705498 Rectal Pain StudyTerminatedNCT00461682Phase 2Results posted
• Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel SyndromeCompletedNCT00421707Phase 2Results posted
• Study to Assess the Effect Of Alosetron On Mucosal Blood FlowCompletedNCT00370032Phase 4Results posted
• A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal SubjectsCompletedNCT02798991Phase 1
• A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy VolunteersCompletedNCT02727283Phase 1
• Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)CompletedNCT01855711Phase 2
• A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679WithdrawnNCT00511563Phase 2
• A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy VolunteersCompletedNCT00401479Phase 1
• A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)CompletedNCT00394186Phase 2
• Effects Of GW876008 On The Bowel In Patients With Irritable Bowel SyndromeCompletedNCT00385099Phase 2
• Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy VolunteersCompletedNCT00376896Phase 1
• Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)CompletedNCT00101985Phase 2
• Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional TherapyCompletedNCT00067561Phase 3
• Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional TherapyCompletedNCT00067457Phase 3